|
|
Post by mango on Jul 22, 2020 20:22:40 GMT -5
So much for DK’s “Veins of gold” comments at the ASM in 2018..... I’m disappointed he is leaving so soon after everything he said. All he accomplished was getting some publications out. I was very excited when Mike first hired him. Huge let down, but I can’t fault Mike for it, Kendall just doesn’t have what it takes to do the job. I guess this really was the easiest job he has ever had (collecting a pay check). |
|
|
|
Post by awesomo on Jul 22, 2020 20:40:55 GMT -5
So much for DK’s “Veins of gold” comments at the ASM in 2018..... I’m disappointed he is leaving so soon after everything he said. All he accomplished was getting some publications out. I was very excited when Mike first hired him. Huge let down, but I can’t fault Mike for it, Kendall just doesn’t have what it takes to do the job. I guess this really was the easiest job he has ever had (collecting a pay check). The common theme in all these executives that have left and were relatively “useless” is Mike. Maybe he’s the one holding everyone back. Just a thought... |
|
|
|
Post by falconquest on Jul 22, 2020 20:49:15 GMT -5
So much for DK’s “Veins of gold” comments at the ASM in 2018..... I’m disappointed he is leaving so soon after everything he said. All he accomplished was getting some publications out. I was very excited when Mike first hired him. Huge let down, but I can’t fault Mike for it, Kendall just doesn’t have what it takes to do the job. I guess this really was the easiest job he has ever had (collecting a pay check). What?!? Let's just take a look at Dr. Kendall shall we?
Dr. Kendall has more than 30 years of experience in diabetes clinical care, education, research and pharmaceutical science. Current responsibilities include medical, research, regulatory, and safety oversight for MannKind’s inhaled mealtime insulin therapy (Technosphere (inhaled human) insulin) and pipeline assets based on the Technosphere platform. He guides clinical, investigator initiated, observational and late phase medical research, development and scientific discovery strategy, late phase clinical development programs, and global medical partnering and regulatory activities. He and his teams are collectively responsibility for scientific thought leader engagement, external medical education, professional relations, medical information and communications.
Prior to joining MannKind in February 2018, Dr. Kendall served as Vice President, Medical Affiars and Distinguished Medical Fellow for Lilly Diabetes (2011-2018). Dr. Kendall also served as Chief Scientific and Medical Officer for the American Diabetes Association (2009-2011) and served in clinical and academic roles as Medical Director and Chief of Clinical and Professional Services at the International Diabetes Center in Minneapolis from 1997-2006 and in 2008-2009. During his tenure at the International Diabetes Center, Dr. Kendall was principle, primary or co-investigator in more than 200 clinical trials.
He served as Executive Medical Director for Amylin Pharmaceuticals from 2005-2008. He has held an academic and clinical appointment as Associate Professor of Medicine at the University of Minnesota from 1997-2005 and 2008-2014 and remained active as a clinician and educator thru 2014.
Dr. Kendall is a professional member of the American Diabetes Association (ADA), the European Association for the Study of Diabetes (EASD) and the American Association of Clinical Endocrinology (AACE). He has been active in diabetes research, education and clinical care for more than 35 years. His research and clinical interests focus on development and application of novel diabetes advancing the use of unique therapies for diabetes care for both type 1 and type 2 diabetes and its complications. As note, while at the International Diabetes Center, he served as a clinical investigator in numerous industry, foundation and federally sponsored clinical research studies including the NIH sponsored Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications (DCCT/EDIC) trial in type 1 diabetes and the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial in type 2 diabetes.
Now let's look at Castgna.....
Dr. Michael E. Castagna Pharm.D. serves as Chief Executive Officer, Director of the Company. Mr. Castagna also served as a Corporate Vice President, Chief Commercial Officer from March 2016 until May 2017. From November 2012 until he joined us, Mr. Castagna was at Amgen, Inc., where he initially served as Vice President, Global Lifecycle Management and was most recently Vice President, Global Commercial Lead for Amgen’s Biosimilar Business Unit. From 2010 to 2012, he was Executive Director, Immunology, at Bristol-Myers Squibb Company (“BMS”). Before BMS, Mr. Castagna served as Vice President and Head, Biopharmaceuticals, North America, at Sandoz, a division of Novartis. Beginning in 1997, he held positions with commercial or medical affairs responsibilities at EMD (Merck) Serono, Pharmasset and DuPont Pharmaceuticals. He received his pharmacy degree from the University of the Sciences-Philadelphia College of Pharmacy, a Pharm.D. from Massachusetts College of Pharmacy & Sciences and an MBA from The Wharton School of Business at the University of Pennsylvania. The Board believes that Mr. Castagna’s knowledge and extensive experience with commercial pharmaceutical companies, combined with his business acumen and judgment, provide our Board with valuable operational expertise and leadership and qualifies him to serve on our Board of Directors.
Dr. Kendall saw the writing on the wall in my opinion. He felt very positive about Afrezza when he joined Mannkind but soon learned that Ooopps! this isn't the easiest job, not because of Afrezza but because of Castagna! Huh, Kendall doesn't have what it takes to do the job eh, that's not what people were saying when he came here. Spin, spin, spin it however you want, Kendall wanted OUT!
|
|
|
|
Post by mango on Jul 22, 2020 21:02:37 GMT -5
I’m disappointed he is leaving so soon after everything he said. All he accomplished was getting some publications out. I was very excited when Mike first hired him. Huge let down, but I can’t fault Mike for it, Kendall just doesn’t have what it takes to do the job. I guess this really was the easiest job he has ever had (collecting a pay check). What?!? Let's just take a look at Dr. Kendall shall we?
Dr. Kendall has more than 30 years of experience in diabetes clinical care, education, research and pharmaceutical science. Current responsibilities include medical, research, regulatory, and safety oversight for MannKind’s inhaled mealtime insulin therapy (Technosphere (inhaled human) insulin) and pipeline assets based on the Technosphere platform. He guides clinical, investigator initiated, observational and late phase medical research, development and scientific discovery strategy, late phase clinical development programs, and global medical partnering and regulatory activities. He and his teams are collectively responsibility for scientific thought leader engagement, external medical education, professional relations, medical information and communications.
Prior to joining MannKind in February 2018, Dr. Kendall served as Vice President, Medical Affiars and Distinguished Medical Fellow for Lilly Diabetes (2011-2018). Dr. Kendall also served as Chief Scientific and Medical Officer for the American Diabetes Association (2009-2011) and served in clinical and academic roles as Medical Director and Chief of Clinical and Professional Services at the International Diabetes Center in Minneapolis from 1997-2006 and in 2008-2009. During his tenure at the International Diabetes Center, Dr. Kendall was principle, primary or co-investigator in more than 200 clinical trials.
He served as Executive Medical Director for Amylin Pharmaceuticals from 2005-2008. He has held an academic and clinical appointment as Associate Professor of Medicine at the University of Minnesota from 1997-2005 and 2008-2014 and remained active as a clinician and educator thru 2014.
Dr. Kendall is a professional member of the American Diabetes Association (ADA), the European Association for the Study of Diabetes (EASD) and the American Association of Clinical Endocrinology (AACE). He has been active in diabetes research, education and clinical care for more than 35 years. His research and clinical interests focus on development and application of novel diabetes advancing the use of unique therapies for diabetes care for both type 1 and type 2 diabetes and its complications. As note, while at the International Diabetes Center, he served as a clinical investigator in numerous industry, foundation and federally sponsored clinical research studies including the NIH sponsored Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications (DCCT/EDIC) trial in type 1 diabetes and the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial in type 2 diabetes.
Now let's look at Castgna.....
Dr. Michael E. Castagna Pharm.D. serves as Chief Executive Officer, Director of the Company. Mr. Castagna also served as a Corporate Vice President, Chief Commercial Officer from March 2016 until May 2017. From November 2012 until he joined us, Mr. Castagna was at Amgen, Inc., where he initially served as Vice President, Global Lifecycle Management and was most recently Vice President, Global Commercial Lead for Amgen’s Biosimilar Business Unit. From 2010 to 2012, he was Executive Director, Immunology, at Bristol-Myers Squibb Company (“BMS”). Before BMS, Mr. Castagna served as Vice President and Head, Biopharmaceuticals, North America, at Sandoz, a division of Novartis. Beginning in 1997, he held positions with commercial or medical affairs responsibilities at EMD (Merck) Serono, Pharmasset and DuPont Pharmaceuticals. He received his pharmacy degree from the University of the Sciences-Philadelphia College of Pharmacy, a Pharm.D. from Massachusetts College of Pharmacy & Sciences and an MBA from The Wharton School of Business at the University of Pennsylvania. The Board believes that Mr. Castagna’s knowledge and extensive experience with commercial pharmaceutical companies, combined with his business acumen and judgment, provide our Board with valuable operational expertise and leadership and qualifies him to serve on our Board of Directors.
Dr. Kendall saw the writing on the wall in my opinion. He felt very positive about Afrezza when he joined Mannkind but soon learned that Ooopps! this isn't the easiest job, not because of Afrezza but because of Castagna! Huh, Kendall doesn't have what it takes to do the job eh, that's not what people were saying when he came here. Spin, spin, spin it however you want, Kendall wanted OUT!
If that were true I would expect Kendall to have seen the writing on the wall before joining. Surely someone of his stature knows how to do due diligence, plus he has the right connections to ask around. I didn’t spin anything, Kendall did very little during his time at MannKind—a handful of publications and some minor language changes in the SoC. Woooptyfuggindoo that does not justify what he was paid during his time at MannKind, IMO. |
|
|
|
Post by mango on Jul 22, 2020 21:04:01 GMT -5
I’m disappointed he is leaving so soon after everything he said. All he accomplished was getting some publications out. I was very excited when Mike first hired him. Huge let down, but I can’t fault Mike for it, Kendall just doesn’t have what it takes to do the job. I guess this really was the easiest job he has ever had (collecting a pay check). The common theme in all these executives that have left and were relatively “useless” is Mike. Maybe he’s the one holding everyone back. Just a thought... That is a possibility... |
|
|
|
Post by buyitonsale on Jul 22, 2020 21:34:27 GMT -5
Kendall did not seem to have any influence with prescribers and did very little to improve Afrezza adoption.
I expected someone with his diabetes pedigree and connections to be more effective in that area.
Will be interesting to see his next move, I hope he is not leaving to work for the big 3 insulin producers... would not surprise me.
|
|
|
|
Post by falconquest on Jul 22, 2020 21:38:57 GMT -5
What?!? Let's just take a look at Dr. Kendall shall we?
Dr. Kendall has more than 30 years of experience in diabetes clinical care, education, research and pharmaceutical science. Current responsibilities include medical, research, regulatory, and safety oversight for MannKind’s inhaled mealtime insulin therapy (Technosphere (inhaled human) insulin) and pipeline assets based on the Technosphere platform. He guides clinical, investigator initiated, observational and late phase medical research, development and scientific discovery strategy, late phase clinical development programs, and global medical partnering and regulatory activities. He and his teams are collectively responsibility for scientific thought leader engagement, external medical education, professional relations, medical information and communications.
Prior to joining MannKind in February 2018, Dr. Kendall served as Vice President, Medical Affiars and Distinguished Medical Fellow for Lilly Diabetes (2011-2018). Dr. Kendall also served as Chief Scientific and Medical Officer for the American Diabetes Association (2009-2011) and served in clinical and academic roles as Medical Director and Chief of Clinical and Professional Services at the International Diabetes Center in Minneapolis from 1997-2006 and in 2008-2009. During his tenure at the International Diabetes Center, Dr. Kendall was principle, primary or co-investigator in more than 200 clinical trials.
He served as Executive Medical Director for Amylin Pharmaceuticals from 2005-2008. He has held an academic and clinical appointment as Associate Professor of Medicine at the University of Minnesota from 1997-2005 and 2008-2014 and remained active as a clinician and educator thru 2014.
Dr. Kendall is a professional member of the American Diabetes Association (ADA), the European Association for the Study of Diabetes (EASD) and the American Association of Clinical Endocrinology (AACE). He has been active in diabetes research, education and clinical care for more than 35 years. His research and clinical interests focus on development and application of novel diabetes advancing the use of unique therapies for diabetes care for both type 1 and type 2 diabetes and its complications. As note, while at the International Diabetes Center, he served as a clinical investigator in numerous industry, foundation and federally sponsored clinical research studies including the NIH sponsored Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications (DCCT/EDIC) trial in type 1 diabetes and the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial in type 2 diabetes.
Now let's look at Castgna.....
Dr. Michael E. Castagna Pharm.D. serves as Chief Executive Officer, Director of the Company. Mr. Castagna also served as a Corporate Vice President, Chief Commercial Officer from March 2016 until May 2017. From November 2012 until he joined us, Mr. Castagna was at Amgen, Inc., where he initially served as Vice President, Global Lifecycle Management and was most recently Vice President, Global Commercial Lead for Amgen’s Biosimilar Business Unit. From 2010 to 2012, he was Executive Director, Immunology, at Bristol-Myers Squibb Company (“BMS”). Before BMS, Mr. Castagna served as Vice President and Head, Biopharmaceuticals, North America, at Sandoz, a division of Novartis. Beginning in 1997, he held positions with commercial or medical affairs responsibilities at EMD (Merck) Serono, Pharmasset and DuPont Pharmaceuticals. He received his pharmacy degree from the University of the Sciences-Philadelphia College of Pharmacy, a Pharm.D. from Massachusetts College of Pharmacy & Sciences and an MBA from The Wharton School of Business at the University of Pennsylvania. The Board believes that Mr. Castagna’s knowledge and extensive experience with commercial pharmaceutical companies, combined with his business acumen and judgment, provide our Board with valuable operational expertise and leadership and qualifies him to serve on our Board of Directors.
Dr. Kendall saw the writing on the wall in my opinion. He felt very positive about Afrezza when he joined Mannkind but soon learned that Ooopps! this isn't the easiest job, not because of Afrezza but because of Castagna! Huh, Kendall doesn't have what it takes to do the job eh, that's not what people were saying when he came here. Spin, spin, spin it however you want, Kendall wanted OUT!
If that were true I would expect Kendall to have seen the writing on the wall before joining. Surely someone of his stature knows how to do due diligence, plus he has the right connections to ask around. I didn’t spin anything, Kendall did very little during his time at MannKind—a handful of publications and some minor language changes in the SoC. Woooptyfuggindoo that does not justify what he was paid during his time at MannKind, IMO. And the truth is we just don't really know, nor will we ever. However, I can look at the qualifications and see that someone is just a bit outclassed. |
|
|
|
Post by bababooey on Jul 22, 2020 22:00:09 GMT -5
Hmmmm....I vividly remember, @sayhey stating as a matter of "FACT" that Dr. Kendal would change the SOC and get Afrezza as a first line treatment. Well geee....looks like his face is covered in pie and not a peep about it him. Not only that, I see he is already onto his next pumping (lying) scheme...Medtronic buying/partnering with MNKD. Does this guy have no dignity? Has he ever been right ONCE in his entire 10+ years holding this stock? Or does he just continue to live in denial?
|
|
|
|
Post by babaoriley on Jul 22, 2020 23:08:20 GMT -5
Hmmmm....I vividly remember, @sayhey stating as a matter of "FACT" that Dr. Kendal would change the SOC and get Afrezza as a first line treatment. Well geee....looks like his face is covered in pie and not a peep about it him. Not only that, I see he is already onto his next pumping (lying) scheme...Medtronic buying/partnering with MNKD. Does this guy have no dignity? Has he ever been right ONCE in his entire 10+ years holding this stock? Or does he just continue to live in denial? Say Hey’s been wrong like most everyone else. But, even if loses his money, he will still be quite smart and literate! |
|
|
|
Post by peppy on Jul 22, 2020 23:28:46 GMT -5
Ok. Let's drive a stake through this myth's heart. A hexamer will disassociate in seconds, arguably in milliseconds, once it hits the blood stream. We know this because people have measured it, and empirically because you can see it every time someone is put on an IV with human insulin. If the myth about hexamers was true then human insulin like Humalin or Novolin would be incredibly slow because they are very hexamer heavy, but in an IV the performance is very rapid. Afrezza is fast because it hits the bloodstream fast, just like IV Novolin. RAA is slow because it has to makes it's way through the subcutaneous layer. Doctors know about insulin states which is why the whole monomer debate is silly and why I usually stay out of it, it's an article of faith. This is also why RAA like the new insulins are adding incipients to get the insulin through the subcutaneous layer faster. Trust me, human interaction is not a natural occurrence at meal times. I don't remember ever seeing a non-diabetic having a quick word with their pancreas about the amount of insulin it should dispense (I do rather like the idea though  The other thing you are overlooking is snacks, meals aren't the only time you eat. Coffee? Better bolus for any milk. Ice cream (to pick a previous example), better suck down another cartridge. Or would you rather have something that means you can be like everyone else and eat whenever and whatever you want without doing anything? Aged - I think you are confusing a couple of things. The problem is the hexamer has to break down into a monomer to get adsorbed through the capillary. If it could push itself into the blood as a hexamer you would be correct but thats not the way it works.Here is a high level discussion on absoption. www.ncbi.nlm.nih.gov/pmc/articles/PMC6079517/When you add in things like hydration levels this whole absorption thing gets a bit complicated. When people eat all the predictability prior to eating/drinking gets thrown out the window. This is why afrezza will always beat an HCL during meals. Afrezza not only stops the spike but will work with the liver if you go too low. As I have said before the HCL and afrezza are like peanut butter and Jelly and I think Galindo thinks this too. The problem is the hexamer has to break down into a monomer to get adsorbed through the capillary. If it could push itself into the blood as a hexamer you would be correct but thats not the way it works. Nice work, thank you for the clarification. Heh Aged, that coffee and ice cream to work your tail. yep. You have been talking about iV insulin a fair share over time. Are you running a continuous IV insulin infusion over there? It has been years, however I remember doing the hourly IV pump checks on the IV Insulin hanging. Have you ever received IV insulin? |
|
|
|
Post by barnstormer on Jul 22, 2020 23:59:06 GMT -5
If that were true I would expect Kendall to have seen the writing on the wall before joining. Surely someone of his stature knows how to do due diligence, plus he has the right connections to ask around. I didn’t spin anything, Kendall did very little during his time at MannKind—a handful of publications and some minor language changes in the SoC. Woooptyfuggindoo that does not justify what he was paid during his time at MannKind, IMO. And the truth is we just don't really know, nor will we ever. However, I can look at the qualifications and see that someone is just a bit outclassed. Mike bragged on many occasions about how he brought Kendall to Mannkind. What a great catch he was. Kendal pontificated about how Afrezza should be the new SOC and that other insulins were barbaric. As far as I can see as an underwater investor who was optimistic that those two would get MNKD on track to at least a double digit (setting the bar low) share price neither are worth the powder it would take to blow them up (euphemisim I'm nonviolent). All I see as hopeful now is that Galindo comes in as CCO and does to Mike just what he did to Matt P when Mike came in as CCO. It's time for a change at the top. I heard Mike presented at another investor conference a couple days ago. Is that true? No PR? I guess he wanted to spare himself from the embarrassment of disapointed shareholders clinging to hope he might actually put a deal together. |
|
|
|
Post by prcgorman2 on Jul 23, 2020 6:55:36 GMT -5
I respect Dr. Kendall. I’m confident this has not been the easiest job he ever had, and I assume that has been frustrating. We like to win. His time at Mannkind was spent doing what he could to mine new results from old data. I think the bumps in share price at the last two ADA conferences are because of Dr. Kendall’s work. But I think the next stage has to be about getting new data and Dr. Kendall may not have been interested. I assume he will be a valuable asset whereever he goes and I’m sorry to see him go and wish him all the best and thank him for his effort. I’ve said repeatedly Mannkind is under-capitalized and his contributions were important during this difficult time for the company.
I don’t understand the comparison of Dr. Kendall as CMO and Dr. Castagna as CCO/CEO. Apples to oranges. It’s like comparing a medical doctor to a pharmacist. They each know their own field better than they know each other’s.
I am interested to see how Galindo fairs in his new job as CCO of Mannkind. He has a device background whereas MC had a drug re-launch background. I think the Rx numbers and revenue improvement YoY seen since the time of Matt Pfeffer are to the credit of MC. I hope Galindo is able to capitalize on BlueHale and help get MNKD to the next level.
Finally, with Dr. Kendall moving on, I assume there will be a CMO opening to fill. Dr. Kendall was a tremendous catch I thought. I don’t see anyway to top that as far as insulin is concerned, so it will be interesting to see if the next CMO is more appropriate to TS pipeline development for other drugs.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 23, 2020 7:12:29 GMT -5
I respect Dr. Kendall. I’m confident this has not been the easiest job he ever had, and I assume that has been frustrating. We like to win. His time at Mannkind was spent doing what he could to mine new results from old data. I think the bumps in share price at the last two ADA conferences are because of Dr. Kendall’s work. But I think the next stage has to be about getting new data and Dr. Kendall may not have been interested. I assume he will be a valuable asset whereever he goes and I’m sorry to see him go and wish him all the best and thank him for his effort. I’ve said repeatedly Mannkind is under-capitalized and his contributions were important during this difficult time for the company. I don’t understand the comparison of Dr. Kendall as CMO and Dr. Castagna as CCO/CEO. Apples to oranges. It’s like comparing a medical doctor to a pharmacist. They each know their own field better than they know each other’s. I am interested to see how Galindo fairs in his new job as CCO of Mannkind. He has a device background whereas MC had a drug re-launch background. I think the Rx numbers and revenue improvement YoY seen since the time of Matt Pfeffer are to the credit of MC. I hope Galindo is able to capitalize on BlueHale and help get MNKD to the next level. Finally, with Dr. Kendall moving on, I assume there will be a CMO opening to fill. Dr. Kendall was a tremendous catch I thought. I don’t see anyway to top that as far as insulin is concerned, so it will be interesting to see if the next CMO is more appropriate to TS pipeline development for other drugs. David Kendall was hired to fill a void at Mannkind. He brought experience and credibility when they needed it the most. Kendall is a Diabetes guy. That's all he knows. If Mannkind brings in a partner to handle the Pediatric Trial, market Afrezza and expand international markets then there's no need for a Diabetes guy. The new partner will also handle all NEW Studies therefore Kendall is not needed. Kendall basically was the man who tried to squeeze blood from a turnip. Kendall helped Mannkind during his short tenure. Mannkind gave us their roadmap when Mike said they are concentrating on COVID & Orphan Lung Diseases. Afrezza will be OUTSOURCED. |
|
|
|
Post by sayhey24 on Jul 23, 2020 7:21:12 GMT -5
Hmmmm....I vividly remember, @sayhey stating as a matter of "FACT" that Dr. Kendal would change the SOC and get Afrezza as a first line treatment. Well geee....looks like his face is covered in pie and not a peep about it him. Not only that, I see he is already onto his next pumping (lying) scheme...Medtronic buying/partnering with MNKD. Does this guy have no dignity? Has he ever been right ONCE in his entire 10+ years holding this stock? Or does he just continue to live in denial? The reality is Dr. Kendall did not get it done, at least not yet. If I could take the blame for that I would. Why he is leaving, I don't know. Is it a health issue, a family issue or something else? Is it the new direction MNKD is taking with Galindo? What we do know is Dr. Kendall is still walking the halls at MNKD so it seems he is leaving on good terms. Will he stay involved to some degree, I don't know. The matter of fact is I am a true believer in afrezza. Everything Al said about afrezza is becoming reality with the exception of it being the greatest selling drug of all time. My hope is Al will be right about this too. Al and Medtronic were in discussions about afrezza when MiniMed was sold. Medtronic wanted to stay focused as a device company at the time. The reality now is U.S. sales are flat. Galindo pitched a plan 4 years ago which was more than being a device company. It included IBM Watson and Sugar IQ. If Galindo can figure out a way to combine his plan from 4 years ago with afrezza and get it covered by insurance we may actually see changes to the SoC. Now, what current BP wants changes when they are making $B's selling SGLT2, GLP1, etc which are obsoleted by afrezza? They will fight these changes with everything they have. We heard all this hype about how HCLs will obsolete the need for afrezza with T1s. Then all the smart people found out the best performance of the HCL is with afrezza, just as Al predicted. A Medtronic/MNKD partnership makes a lot more sense to disrupt the market than a BP/MNKD partnership where the BP is making $B selling other diabetes drugs. Time will tell what Galindo brings to the party. I hope Dr. Kendall stays in the picture as best he can. BTW - I really like chocolate cream pie. |
|
|
|
Post by uvula on Jul 23, 2020 7:43:29 GMT -5
I wonder how many years mnkd will continue paying kendal after he leaves. This could give us a clue as to whether he quit or was forced out.
|
|
The other thing you are overlooking is snacks, meals aren't the only time you eat. Coffee? Better bolus for any milk. Ice cream (to pick a previous example), better suck down another cartridge. Or would you rather have something that means you can be like everyone else and eat whenever and whatever you want without doing anything?
